Retraction: Re: Ling Y-H, Lin R, and Perez-Soler R (2008) Erlotinib Induces Mitochondrial-Mediated Apoptosis in Human H3255 Non-Small-Cell Lung Cancer Cells with Epidermal Growth Factor ReceptorL858R Mutation through Mitochondrial Oxidative Phosphorylation-Dependent Activation of BAX and BAK Mol Pharmacol 74:793-806; doi:10.1124/mol.107.044396 (Molecular pharmacology (2008) 74 3 (793-806));Erlotinib induces mitochondrial-mediated apoptosis in human H3255 non-small-cell lung cancer cells with epidermal growth factor receptor L858R mutation through mitochondrial oxidative phosphorylation- dependent activation of BAX and BAK

Molecular Pharmacology

Volumn 74, Issue 3, 2008, Pages 793-806

  Ling, Yi He ^a   Lin, Ruoping ^a   Perez Soler, Roman ^a,b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMYCIN A1; BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; CASPASE 8; CYTOCHROME C; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FAS ANTIGEN; OLIGOMYCIN; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BID; ROTENONE; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL DEATH; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; ENZYME ACTIVATION; GENE MUTATION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; OXIDATIVE PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

EID: 50449087729     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.115.08er15b     Document Type: Erratum

References (43)

1. Adams JM and Cory S (2001) Life-or-death decision by the Bcl-2 protein family. Trends Biochem Sci 26:61-66.
2. Annis MG, Soucie EL, Dlugosz PJ, Cruz-Aguado JA, Penn LZ, Leber B, and Andrews DW (2005) Bax form multispanning monomers that oligomerize to permeabilize membranes during apoptosis. EMBO J 24:2096-2103.
3. Antignani A and Youle RJ (2006) How do Bax and Bak lead to permeabilization of the out mitochnodrial membrane? Curr Opin Cell Biol 18:685-689.
4. Costa DB, Halmos B, Kumar A, Schumer ST, Huberman MS, Boggon TJ, Tenen DG, and Kobayashi S (2007) BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancer with oncogenic EGFR mutations. PLoS Med 4:e315.
5. Cragg MS, Kuroda J, Puthalakath H, Huang DCS, and Strasser A (2007) Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics. PLoS Med 4:e316.
6. Dai Q, Ling YH, Lia M, Zou YY, Kroog G, Iwata KK, and Perez-Soler R (2005) Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines. Clin Cancer Res 11:1572-1578.
7. Deng J, Shimamura T, Perera S, Carlson NE, Cai D, Shapiro GI, Wong KK, and Letai A (2007) Proapoptotic BH3-only bcl-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion. Cancer Res 67:11867-11875.
8. Desagher S and Martinou JC (2000) Mitochondria as the central control point of apoptosis. Trends Cell Biol 10:369-3777.
9. Gong Y, Somwar R, Politi K, Balak M, Chmielecki J, Jiang X, and Pao W (2007) Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas. PLoS Med 4:e294.
10. Green DR (2000) Apoptotic pathways: paper wraps stone blunts scissors. Cell 102:1-4.
11. Gross A, Jockel J, Wei MC, and Korsmeyer SJ (1998) Enforced dimerization on Bax results in its translocation, mitochondrial dysfunction and apoptosis. EMBO J 17:3878-3885.
12. Harris RC and Daniel TO (1989) Epidermal growth factor binding, stimulation of phosphorylation, and gluconeogenesis in rat proximal tubule. J Cell Physiol 139:383-391.
13. Huang DC and Strasser A (2000) BH3-only proteins-essential initiators of apoptotic cell death. Cell 103:839-842.
14. Karbowski M, Norris KL, Cleland MM, Jeong SY, and Youle RJ (2006) Role of Bax and Bak in mitochondrial morphogenesis. Nature 443:658-662.
15. Kaufmann SH and Earnshaw WC (2000) Induction of apoptosis by cancer chemotherapy. Exp Cell Res 256:42-49.
16. Kroemer G, Petit P, Zamzami N, Vayssière JL, and Mignotte B (1995) The biochemistry of programmed cell death. FASEB J 9:1277-1287.
17. Kuroda J, Puthalakath H, Cragg MS, Kelly PN, Bouillet P, Huang DC, Kimura S, Ottmann OG, Druker BJ, Villunger A, et al. (2006) Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukic cells, and resistance due to their loss id overcome by a BH3 mimetic. Proc Natl Acad Sci U S A 103:14907-14912.
18. Li H, Zhu H, Xu CJ, and Yuan J (1998) Cleavage of BID by caspase 8 mediated the mitochondrial damage in the Fas pathway of apoptosis. Cell 98:481-490.
19. Ling YH, Liebes L, Zou Y, and Perez-Soler R (2003) Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells. J Biol Chem 278:33714-33723.
20. 1/S phase arrest inhuman non-small-cell lung cancer cell lines. Mol Pharmacol 72:248-258.
21. Linnett PE and Beechey RB (1979) Inhibitors of the ATP synthetase systems. Methods Enzymol 55:472-518.
22. Liu B and Fan Z (2001) The monoclonal antibody 225 activates caspase-8 and induces apoptosis through a tumor necrosis factor receptor family-independent pathway. Oncogene 20:3726-3734.
23. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139.
24. Majewski N, Nogueira V, Robey RB, and Hay N (2004) Akt inhibits apoptosis downstream of BID cleavage via a glucose-dependent mechanism involving mitochondrial hexokinases. Mol Cell Biol 24:730-740.
25. Moyer JD, Barbacci EG, Iwata KK, Arnold L, Boman B, Cunningham A, DiOrio C, Doty J, Morin MJ, Moyer MP, et al. (1997) Induction of apoptosis and cell cycle arrest by OSI-774, an inhibitor of epidermal growth factor tyrosine kinase. Cancer Res 57:4838-4848.
26. Noonberg SB and Benz CC (2000) Tyrosine kinase inhibitions targeted to the epidermal growth factor receptor subfamily: role as anticancer agents. Drugs 59:753-767.
27. Okun JG, Lümmen P, and Brandt U (1999) Three classes of inhibitors share a common binding domain in mitochondrial complex I (NADH:ubiquinone oxidoreductase. J Biol Chem 274:2625-2630.
28. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et al. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497-1500.
29. Panaretakis T, Pokrovskaja K, Shoshan MC, and Grandér D (2002) Activation of Bak, Bax, and BH3-only proteins in the apoptotic response to doxorubicin. J Biol Chem 277:44317-44326.
30. Pollack VA, Savage DM, Baker DA, Tsaparikos KE, Sloan DE, Moyer JD, Barbacci EG, Pustilnik LR, Smolarek TA, Davis JA, et al. (1999) Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinoma with OSI-774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J Pharmacol Exp Ther 291:739-748.
31. Reed JC (2002) Apoptosis-based therapies. Nat Rev Drug Discov 1:111-121.
32. Salomon DS, Brandt R, Ciardiello F, and Normanno N (1995) Epidermal growth factor-related peptides and their receptor in human malignancies. Crit Rev Oncol Hematol 19:183-232.
33. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, et al. (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123-132.
34. Stankiewicz AR, Lachapelle G, Foo CP, Radicioni SM, and Mosser DD (2005) Tumor necrosis factor-α induces Bax-Bak interaction and apoptosis, which is inhibited by adenovirus E1B 19K. J Biol Chem 280:38729-38739.
35. Sundararajan R, Cuconati A, Nelson D, and White E (2001) Tumor necrosis factor-α induces Bax-Bak interaction and apoptosis, which is inhibited by adenovirus E1B 19K. J Biol Chem 276:45120-45127.
36. Suzuki M, Youle RJ, and Tjandra N (2000) Structure of Bax: coregulation of dimmer formation and intracellular localization. Cell 103:645-654.
37. Tomiyama A, Serizawa S, Tachibana K, Sakurada K, Samejima H, Kuchino Y, and Kitanaka C (2006) Critical role for mitochondrial oxidative phosphorylation in the activation of tumor suppression Bax and Bak. J Natl Cancer Inst 98:1462-1473.
38. L858R non-small-cell lung cancer cell line H3255. Cancer Res 64:7241-7744.
39. Walczak H and Krammer PH (2000) The CD95 (APO-1/Fas) and TRAIL (APO-2L) apoptosis system. Exp Cell Res 256:58-66.
40. Yamaguchi H and Wang HG (2002) Bcl-XL protects Bim-induced Bax conformational change and cytochrome c release independent of interacting with Bax or BinEL. J Biol Chem 277:41604-41612.
41. Yarden Y and Ullrich A (1988) Growth factor receptor tyrosine kinases. Annu Re. Biochem 57:443-478.
42. Yarden Y and Sliwkowski MX (2001) Untangling the ErbB signaling network. Nat Rev Mol Cell Biol 2:127-137.
43. 3) induces apoptosis through activation of bax hematopoietic cells. Oncogene 24:3339-3347.